JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT), 'Upside Remains on Raised Full EU Approval Outlook'
Tweet Send to a Friend
JPMorgan analyst Eric Joseph reiterated an Overweight rating on PTC Therapeutics (NASDAQ: PTCT)The analyst comments "On the whole, we view ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
